Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(1 year, 6 months from now) | |
US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(3 years from now) | |
US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(6 years from now) | |
US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(6 years from now) | |
US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(6 years from now) | |
US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(6 years from now) | |
US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(6 years from now) | |
US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(6 years from now) | |
US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(7 years from now) |
Drugs and Companies using ILOPERIDONE ingredient
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering ilo...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(1 year, 3 months ago) | |
US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(10 years from now) | |
US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24 ho...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(1 year, 3 months ago) | |
US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(10 years from now) | |
US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime...
Dosage: SUSPENSION;ORAL